1. Home
  2. BIO vs SF Comparison

BIO vs SF Comparison

Compare BIO & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIO
  • SF
  • Stock Information
  • Founded
  • BIO 1952
  • SF 1890
  • Country
  • BIO United States
  • SF United States
  • Employees
  • BIO N/A
  • SF N/A
  • Industry
  • BIO Biotechnology: Laboratory Analytical Instruments
  • SF Investment Bankers/Brokers/Service
  • Sector
  • BIO Industrials
  • SF Finance
  • Exchange
  • BIO Nasdaq
  • SF Nasdaq
  • Market Cap
  • BIO 9.5B
  • SF 9.0B
  • IPO Year
  • BIO N/A
  • SF N/A
  • Fundamental
  • Price
  • BIO $343.61
  • SF $101.52
  • Analyst Decision
  • BIO Strong Buy
  • SF Hold
  • Analyst Count
  • BIO 4
  • SF 7
  • Target Price
  • BIO $381.50
  • SF $96.67
  • AVG Volume (30 Days)
  • BIO 182.3K
  • SF 464.0K
  • Earning Date
  • BIO 10-30-2024
  • SF 10-23-2024
  • Dividend Yield
  • BIO N/A
  • SF 1.66%
  • EPS Growth
  • BIO N/A
  • SF N/A
  • EPS
  • BIO N/A
  • SF 4.71
  • Revenue
  • BIO $2,562,604,000.00
  • SF $4,551,923,000.00
  • Revenue This Year
  • BIO N/A
  • SF $15.75
  • Revenue Next Year
  • BIO $4.49
  • SF $8.35
  • P/E Ratio
  • BIO N/A
  • SF $21.57
  • Revenue Growth
  • BIO N/A
  • SF 5.88
  • 52 Week Low
  • BIO $261.59
  • SF $54.81
  • 52 Week High
  • BIO $364.24
  • SF $103.32
  • Technical
  • Relative Strength Index (RSI)
  • BIO 55.67
  • SF 75.89
  • Support Level
  • BIO $338.84
  • SF $95.44
  • Resistance Level
  • BIO $350.53
  • SF $103.32
  • Average True Range (ATR)
  • BIO 7.98
  • SF 1.59
  • MACD
  • BIO 0.24
  • SF 0.38
  • Stochastic Oscillator
  • BIO 67.74
  • SF 82.74

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

About SF Stifel Financial Corporation

Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 60% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.

Share on Social Networks: